GFM
PCVX icon

GF Fund Management’s Vaxcyte PCVX Stock Holding History

GF Fund Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Buy
2,940
+368
+14% +$20K ﹤0.01% 296
2025
Q4 		$119K Sell
2,572
-221
-8% -$9.88K ﹤0.01% 335
2025
Q3 		$101K Sell
2,793
-399
-13% -$13.2K ﹤0.01% 336
2025
Q2 		$104K Hold
3,192
– – ﹤0.01% 361
2025
Q1 		$121K Buy
3,192
+575
+22% +$46K ﹤0.01% 351
2024
Q4 		$214K Buy
+2,617
New +$260K ﹤0.01% 287

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GF Fund Management's PCVX Position: Q1 2026 in Review

GF Fund Management increased its Vaxcyte (PCVX) stake by 14% in Q1 2026, buying an estimated $20K and bringing the position to 2,940 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

GF Fund Management first reported a position in PCVX in Q4 2024 and has held it in 6 quarters since. The position peaked at $214K in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • GF Fund Management held 2,940 shares of Vaxcyte worth $171K as of Q1 2026.
  • GF Fund Management bought 368 Vaxcyte shares in Q1 2026, an estimated $20K.
  • Vaxcyte made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #296 holding.
  • GF Fund Management first reported a position in Vaxcyte in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Vaxcyte position peaked at $214K in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.